Product Description
Mechanisms of Action: Free Radical Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Quintiles IMS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Temoporfin](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Cholangiocarcinoma
Phase 2: Squamous Cell Carcinoma|Head and Neck Cancer|Ductal Carcinoma|Nasopharyngeal Cancer|Oncology Unspecified|Klatskin Tumor|Cholangiocarcinoma
Phase 1: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CARP | P4 |
Unknown Status |
Cholangiocarcinoma |
2027-12-31 |
|
PDT | P2 |
Completed |
Cholangiocarcinoma|Klatskin Tumor |
2023-04-12 |
|
I 228112 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2018-09-04 |
|
NCT01637376 | P1 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2014-01-01 |